WELLINGTON MANAGEMENT GROUP LLP 13D and 13G filings for Revance Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-04 09:29 am Sale | 2021-12-31 | 13G | Revance Therapeutics, Inc. RVNC | WELLINGTON MANAGEMENT GROUP LLP | 1,104,531 1.540% | -2,293,341 (-67.49%) | Filing |
| 2021-02-04 11:42 am Sale | 2020-12-31 | 13G | Revance Therapeutics, Inc. RVNC | WELLINGTON MANAGEMENT GROUP LLP | 3,397,872 5.110% | -345,828 (-9.24%) | Filing |
| 2020-08-10 09:43 am Sale | 2020-07-31 | 13G | Revance Therapeutics, Inc. RVNC | WELLINGTON MANAGEMENT GROUP LLP | 3,743,700 5.680% | -2,044,345 (-35.32%) | Filing |